Top KHN Original Stories

Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?

In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.

View More

Total Results: 12060

Post-Surgical Patients Are Rarely The Ones Who Start Long-Term Opioid Use

KHN Morning Briefing

Its more common for those who receive their first prescription for back pain or “other ill-defined conditions” to go on to use painkillers for six months or more, according to new research. In other news related to the national epidemic, the Cherokee Nation asks a judge to allow its lawsuit against opioid distributors and retailers to be heard in the tribe’s own court. And KHN reports that the public health crisis is taking a toll on the nation’s foster care system.

FDA Issues New Approvals For Leukemia, Ovarian Cancer Medicines

KHN Morning Briefing

The Food and Drug Administration approves a new Pfizer drug to treat a rare, fast-progressing form of leukemia. The agency also expands the use Lynparza, sold by AstraZeneca and Merck & Co, to treat recurrent ovarian cancer. In other pharmaceutical news, changes to 340B program are delayed and a biopharma executive encounters challenges when trying to fund his own project.

Settlement Finalized Between Mylan, Feds Over Epipen Overcharges To Medicaid

KHN Morning Briefing

The $465 million settlement announced Thursday by the Department of Justice resolves claims that Mylan avoided paying rebates to the government by improperly classifying the EpiPen as a generic drug. Mylan and its auto-injector product have been at the center of the national debate over prescription drug costs.

Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?

KHN Original

In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.

Kansas’ Osawatomie State Hospital Passes Inspection

KHN Morning Briefing

The psychiatric hospital lost its certification in 2015, which resulted in a loss of about $1 million a month in federal funding for the state, but it now appears to be back on track. Meanwhile, in Oregon, Willamette Valley Behavioral Health plans to sue the state over the rejection of its plan to build a 100-bed psychiatric hospital. In addition, the cause of the illness at New Hampshire’s Exeter Hospital is still unclear and two Florida cancer centers face fraud allegations.

Hacks Targeting Health Care Data Spike 162% Over Last Year

KHN Morning Briefing

Security experts account for the jump by saying that hacking has gotten easier and more organizations are now reporting incidents. Meanwhile, Bayada Home Health Care and St. Luke’s Health System also make industry news.

UnitedHealth CEO Stephen Hemsley Steps Down

KHN Morning Briefing

The insurer’s current president David Wichmann will take over the position while Hemsley, who has been with the health plan since 1997, will move into a newly created role as executive chairman of the board of directors.

What To Do If A Medical Bill Triggers Sticker Shock?

KHN Morning Briefing

The Wall Street Journal suggests that consumers should negotiate medical costs, question charges and move quickly to resolve disputes or arrange payment plans. In another story, the Journal notes a trend in which consumers appear less anxious for the latest treatment or medical technology when it also is the most expensive.